EP2734181A2 - Agent de traitement capillaire tensioactif contenant de la poly-l-lysine ii - Google Patents

Agent de traitement capillaire tensioactif contenant de la poly-l-lysine ii

Info

Publication number
EP2734181A2
EP2734181A2 EP12725415.9A EP12725415A EP2734181A2 EP 2734181 A2 EP2734181 A2 EP 2734181A2 EP 12725415 A EP12725415 A EP 12725415A EP 2734181 A2 EP2734181 A2 EP 2734181A2
Authority
EP
European Patent Office
Prior art keywords
weight
hair treatment
surfactant
preferred
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12725415.9A
Other languages
German (de)
English (en)
Inventor
Erik Schulze Zur Wiesche
Volker Scheunemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP2734181A2 publication Critical patent/EP2734181A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88—Polyamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • the invention relates to a cosmetic hair treatment agent based on a specific combination of active ingredients, a method using the means and the use of the means for the prophylaxis, reduction, elimination and alleviation of dandruff on hairy body surfaces.
  • Skin and hair cleansers such as those commercially available as liquid soaps, shampoos, shower baths, bubble baths, shower gels, and wash gels, not only must have good detergency, but should also be well tolerated by the skin and hair if used frequently, do not cause excessive defatting or dryness.
  • dandruff An important aspect of hair cleansing and care is the fight against dandruff, because even the slight appearance of dandruff on the scalp or other hairy body regions is considered a sign of lack of care.
  • dandruff is usually accompanied by itching, which is perceived as disturbing. Itching, on the other hand, causes scratching reactions, which can lead to injuries of the affected skin, which in turn can form the basis for infections and pathogenic agents.
  • the requirements for a cosmetic remedy for dandruff are therefore high, because on the one hand the scalp should be thoroughly and permanently freed of dandruff, and on the other hand, the remedy for hair and scalp should be well tolerated.
  • Another important requirement is to have the fastest possible effect, so that the above-mentioned chain of disadvantages does not occur at all.
  • the present invention relates to compositions for the treatment of hair and the scalp, containing - based on their weight - a)> 6 wt .-% surfactant (s), preferably> 10 wt .-% surfactant (e)
  • n stands for integers between 5 and 100
  • compositions according to the invention are surfactant-containing and contain a total amount of at least 6% by weight of surfactant (s).
  • the content of the agents is limited to anionic and cationic surfactants, since at least 80 wt .-% of all surfactants used in the compositions of the invention originate from the groups of amphoteric and / or nonionic surfactants. In preferred agents according to the invention, these limits are further apart.
  • Agents preferred according to the invention contain a total amount of at least 10% by weight of surfactant (s) and at the same time have a content of amphoteric and / or nonionic surfactants of at least 90% by weight, based on the total amount of surfactant.
  • Very particularly preferred hair treatment agents according to the invention are characterized in that they contain 6 to 40% by weight, preferably 10 to 35% by weight, more preferably 12 to 30% by weight, even more preferably 14 to 25% by weight and in particular 15 to 25 wt .-% surfactant (s) included.
  • the agents according to the invention contain amphoteric surfactant (s).
  • Ampholytic surfactants and emulsifiers are surface-active compounds which, apart from a C 8 - contain at least one free amino group and at least one -COOH or -S0 3 H group and alkyl or acyl group capable of forming inner salts - C 2 4 are.
  • ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidoproylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids with each about 8 to 24 carbon atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C 12 -C 18 acylsarcosine.
  • compositions according to the invention are characterized in that they contain amphoteric surfactant (s) from the groups of
  • Alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group
  • N-alkyl-N, N-dimethylammonium glycinates for example cocoalkyldimethylammonium glycinate,
  • N-acylaminopropyl-N, N-dimethylammonium glycinates for example cocoacylaminopropyl-dimethylammonium glycinate,
  • amphoteric surfactant (s) in amounts of 0.5 to 9 wt .-%, preferably from 0.75 to 8 wt .-% and in particular from 1 to 7.5 wt .-%, each based on the total agent included.
  • Particularly preferred hair treatment compositions contain as amphoteric surfactants betaines of the formula (Bet-I)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
  • Cocoamidopropylbetaine Representatives derived from coconut fatty acids, are preferred and are referred to as Cocoamidopropylbetaine. According to the invention, particular preference is given to using surfactants of the formula (Bet-I) which are a mixture of the following representatives:
  • agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (Bet-I) included.
  • the hair-treatment compositions of the invention may be used with particular preference as amphoteric surfactants betaines of the formula (Bet-II)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
  • These surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.
  • surfactants of this type always also contain betaines of the formula (Bet-IIa)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms and M is a cation.
  • surfactants are referred to according to the INCI nomenclature as Amphodiacetate, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamphodiactetate.
  • agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (Bet-II) included.
  • hair treatment compositions according to the invention are preferred in which the radical R in the formulas (Bet-I) and (Bet-II) is selected from
  • compositions of the invention may also contain nonionic surfactants.
  • alkyl polyglycosides are nonionic surfactants made entirely from renewable resources (sugar building blocks, predominantly glucose, for example from corn starch and fatty alcohol, for example from coconut oil). Alkyl polyglycosides are accessible by acid-catalyzed reaction (Fischer reaction) of sugars, especially glucose (or starch) or butyl glycosides with fatty alcohols.
  • alkyl monoglucoside alkyl- ⁇ -D- and ⁇ -D-glucopyranoside and small amounts of glucofuranoside
  • alkyldiglucosides -isomaltosides, maltosides, etc.
  • alkyl oligoglucosides maltotriosides, tetraosides, etc.
  • the average degree of polymerization of commercial products whose alkyl radicals are in the range C8-C16 is 1, 2-1, 5.
  • alkylpolyglycosides corresponding to the general formula RO - (Z) x , where R is alkyl, Z is sugar and x is the number of sugar units.
  • R is alkyl
  • Z is sugar
  • x is the number of sugar units.
  • sugar building block Z it is possible to use any desired mono- or oligosaccharides.
  • sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used.
  • Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose.
  • preferred hair treatment compositions according to the invention are characterized in that they - based on their weight - 0, 1 to 20 wt .-%, preferably 1 to 10 wt .-% and in particular 2 to 8 wt .-% alkylpolyglycoside (e) of the formula
  • n is from 5 to 21, preferably from 7 to 19, more preferably from 9 to 17 and especially from 1 to 13, and k is from 1 to 1 to 8, preferably from 1 to 2 1, 5, and Z stands for a sugar unit from the group glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Glucose is a particularly preferred sugar building block (Z), so that preferred hair treatment compositions according to the invention are characterized in that they are based on their weight - 0.1 to 15 wt .-%, preferably 1 to 10 wt .-% and in particular 2 to 8 Wt .-% Alkylpolyglucosid (e) of the formula
  • n is from 5 to 21, preferably from 7 to 19, more preferably from 9 to 17 and especially from 1 to 13, and m is from 1 to 1 to 8, preferably from 1 to 2 1, 5 stand.
  • alkylpolyglycosides which can be used according to the invention contain on average 1, 1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 8.
  • Very particularly preferred alkypolyglucosides are those whose alkyl radical is a lauryl radical.
  • particularly preferred hair treatment compositions according to the invention are characterized in that they are based on their weight - 0.1 to 15 wt .-%, preferably 1 to 10 wt .-% and in particular 2 to 8 wt .-% Alkylpolyglucosid (e) of the formula
  • n stands for the value 1 1 m for values of 1, 1 to 1, 8, preferably from 1, 2 to 1, 5 stand.
  • preferred hair treatment agents according to the invention are characterized in that they contain 5 to 30% by weight, preferably 6 to 25% by weight, more preferably 7 to 20% by weight, even more preferably 8 to 15% by weight and in particular 10 to 12.5 wt .-% amphoteric (s) and / or nonionic surfactant (s) included.
  • Hair treatment agents according to the invention which are less than 1, 5 wt .-%, preferably less than 1, 25 wt .-%, more preferably less than 1 wt .-%, even more preferably less than 0.5 wt .-% and in particular less than 0.05% by weight of anionic surfactant (s).
  • compositions of the invention contain poly-L-lysine, an oligo- or polymer of the natural amino acid lysine, which is also referred to as Epsilon-polylysine due to its linkage in epsilon position.
  • Epsilon-polylysine due to its linkage in epsilon position.
  • compositions of the invention epsilon-poly-L-lysine is used within narrower ranges.
  • Hair treatment agents preferred according to the invention are characterized in that they contain from 0.0005 to 4, preferably from 0.001 to 3, more preferably from 0.005 to 2 and in particular from 0.01 to 1% by weight of epsilon-poly-L-lysine of the general formula (I).
  • the degree of polymerization of the epsilon-poly-L-lysines used according to the invention is between 5 and 100. Depending on the hair treatment agent and use concentration, it was possible to observe an optimum effect for polymers within narrower degrees of polymerization. Accordingly, hair treatment agents of the invention containing epsilon-poly-L-lysine of the general formula (I) are preferred in which n is an integer of 10 to 70, preferably 15 to 60, more preferably 20 to 50 and especially numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 stands.
  • Very particularly preferred hair treatment compositions according to the invention contain
  • Hair treatment composition according to Claim 6 characterized in that it contains the moisturizing active substance (s) in amounts of 0.1 to 10% by weight, preferably 0.15 to 7.5% by weight, more preferably 0 , 2 to 5 wt .-% and in particular from 0.25 to 4 wt .-%.
  • compositions according to the invention can be further enhanced by using certain care substances.
  • these are selected from certain groups of known care substances, since these care substances harmonize perfectly with the formulation and the care effect with the combination used according to the invention against dandruff.
  • Hair treatment compositions which are preferred according to the invention are characterized in that they additionally have care substance (s), based on their weight, in amounts of from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5 Wt .-% and in particular 0.05 to 2.5 wt .-%, with preferred care substance (s) are selected from the group i. L-carnitine and / or its salts;
  • L-carnitine (IUPAC name (R) - (3-carboxy-2-hydroxypropyl) -A /, A /, A / -trimethylammonium hydroxide) is a naturally occurring, vitamin-like substance. It plays an essential role in the energy metabolism of human, animal and plant cells. L-carnitine can be obtained in various ways on an industrial scale. For example, a biotechnological process that imitates the body's own biosynthesis: In large fermentation tanks, the precursor of L-carnitine ( ⁇ -butyrobetaine) is converted into L-carnitine with the help of qramneqative bacteria (rhizobia).
  • L-carnitine can form addition compounds and double salts.
  • L-carnitine derivatives which are preferred according to the invention are selected in particular from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and particularly preferably L-carnitine tartrate.
  • the L-carnitine compounds mentioned are available, for example, from Lonza GmbH (Wuppertal, Germany).
  • Preferred hair treatment compositions according to the invention are characterized in that they contain from -0.001 to 10% by weight, preferably 0.005 to 7.5% by weight, particularly preferably 0.01 to 5% by weight and in particular 0.05% by weight contain up to 2.5% by weight of L-carnitine or L-carnitine derivatives, preferred L-carnitine derivatives being selected from acetyl-L- Carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl L-carnitine and in particular L-carnitine tartrate.
  • preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).
  • compositions of the invention are also preferred.
  • Vitamins provitamins or vitamin precursors. These are described below:
  • vitamin A includes retinol (vitamin Ai) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • a component according to the invention for example, vitamin A acid and its esters,
  • Vitamin A aldehyde and vitamin A alcohol and its esters such as palmitate and acetate in
  • the agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • the vitamin B group or the vitamin B complex include u. a.
  • Vitamin B 2 (riboflavin)
  • Vitamin B 3 the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 5 pantothenic acid, panthenol and pantolactone. Panthenol and / or pantolactone are preferably used in the context of this group (see below).
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are, for example, the panthenol triacetate, the panthenol monoethyl ether and its monoacetate and also the cationic panthenol derivatives disclosed in WO 92/13829.
  • the said compounds of the vitamin B 5 type are preferably contained in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin B 6 pyridoxine and pyridoxamine and pyridoxal.
  • Vitamin C (ascorbic acid). Vitamin C is used in the inventive compositions preferably in amounts of 0, 1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as acetate, nicotinate, phosphate and succinate, are in the inventive compositions preferably in amounts of 0.05-1 wt .-%, based on the total agent.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-cf] - imidazole-4-valeric acid, for which, however, the common name biotin has become established.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H.
  • vitamin B 5 2,4,4-dihydroxy-A / - (3-hydroxypropyl) -3,3-dimethylbutyramide, provitamin B 5 ) and / or pantothenic acid (vitamin B 3 , vitamin B 5 ) and / or Niacin, niacinamide or nicotinamide (vitamin B 3 ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin B) and / or riboflavin (vitamin B 2 , vitamin G) and / or biotin (vitamin B 7 , vitamin H) and / or folic acid (vitamin B 9 , vitamin B c or vitamin M) and / or vitamin B 6 and / or vitamin B 2 .
  • compositions according to the invention can therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)
  • X, Y, Z are independently -O- or -NH- or NR 4 - or a chemical bond
  • R, R 2 , R 3 independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C 1 -C 6 ) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (C 1 -C 6 ) - Alkylene group, or a (Ci-Ce) acyl radical, wherein preferred radicals are independently selected from -H, CH3, -CH2CH3, - (CH2) 2CH2, -CH (CH3) 2, - (CH2) 3CH3, -CH (CH 3 ) CH 2 CH 3 , - CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3 R 4 is -CH 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 2 , -CH (CH 3 ) 2 ,
  • n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0, 1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)
  • n 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10).
  • the agents according to the invention may also contain plastoquinones.
  • preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)
  • n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula
  • the agents according to the invention may contain.
  • the agents according to the invention may contain ectoin.
  • Ectoine ((4S) - 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylic acid) is a natural product belonging to the group of compatible solutes. The highly water-binding low molecular weight organic compound occurs in halophilic bacteria and allows these extremophilic organisms to survive under stress conditions.
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.
  • S -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid
  • hydroxyectoine hydroxyectoine
  • compositions according to the invention may contain purine and / or purine derivatives as a care substance.
  • purine and / or purine derivatives with ubiquinones and / or plastoquinones as a care substance means that the hairs treated with corresponding agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.
  • Purine (7H-imidazo [4,5-d] pyrimidine) does not occur freely in nature, but forms the main body of the purines.
  • Purines are a group of important compounds of widespread nature involved in human, animal, plant and microbial metabolic processes, which differ from the parent by substitution with OH, NH 2 , SH in the 2-, 6-, and 8-positions and / or with CH 3 in 1-, 3-, 7-position derived.
  • Purine can be prepared, for example, from aminoacetonitrile and formamide.
  • Purines and purine derivatives are often isolated from natural products, but are also synthetically accessible in many ways.
  • Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges.
  • inventively preferred cosmetic agents characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% purine (s) and / or purine derivative (s).
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain as care substance - based on their weight - from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s), preferred agents containing purine and / or purine derivative (s) of formula (Pur-I)
  • radicals R, R 2 and R 3 are independently selected from -H, - OH, NH 2 , -SH and the radicals R 4 , R 5 and R 6 are independently selected from -H, -CH 3 and -CH 2 - CH 3 , the following compounds being preferred:
  • agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) is 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and in particular 1: 1 to 1:10.
  • caffeine is a particularly preferred purine derivative
  • coenzyme Q10 is a particularly preferred biochinone.
  • Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included.
  • the compositions of the invention may also contain flavonoids.
  • the flavonoids are a group of water-soluble plant dyes and play an important role in the metabolism of many plants. They belong together with the phenolic acids to the polyphenols. There are well over 6500 different flavonoids known, which can be divided into flavonols, flavones, flavanones, isoflavonoids and anthocyanins.
  • flavonoids from all six groups can be used, with certain representatives from the individual groups as a care substance because of their particularly intense Effect are preferred.
  • Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.
  • particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% flavonoids, especially flavonols, more preferably 3,3 ', 4', 5,7-Pentahydroxyflavon (quercetin) and / or 3,3 ', 4', 5,7-Pentahydroxyflavon -3-0-rutinoside (rutin), included.
  • hair treatment compositions according to the invention which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1, 5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol.
  • Creatine is also suitable as a care substance according to the invention.
  • Creatine (3-methylguanidinoacetic acid) is an organic acid found in vertebrates and the like. a. contributes to supplying the muscles with energy. Creatine is synthesized in the kidney, liver and pancreas. It is formally derived from the amino acids glycine and arginine and is 95% present in skeletal muscle.
  • Particularly preferred hair treatment compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 bis 7.5 wt .-% and in particular 0.5 to 5 wt .-% / V-methyl guanidino-acetic acid (creatine).
  • compositions according to the invention may contain, in addition to the ingredients mentioned above and optional further ingredients, other substances which prevent, alleviate or cure hair loss.
  • other substances which prevent, alleviate or cure hair loss.
  • a content of hair root stabilizing agents is advantageous.
  • Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone.
  • Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.
  • spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application.
  • Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.
  • hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.
  • the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.
  • the agents according to the invention may with particular preference contain one or more amino acids.
  • Particularly preferred amino acids which can be used according to the invention are from the group of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, ⁇ Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cy
  • Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges.
  • preferred hair treatment compositions are characterized in that they as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1, 5 Wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group of glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.
  • the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides.
  • preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt.
  • carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected from monosaccharides, in particular D-ribose and / or D-xylose and / or L-arabinose and / or D-glucose and / or D-mannose and / or D-galactose and / or D-fructose and / or sorbose and / or L-fucose and / or L-rhamnose, disaccharides, in particular sucrose and / or maltose and / or lactose and / or trehalose and / or cellobiose and / or gentiobiose and / or isomaltose.
  • Particularly preferred agents according to the invention contain based on their weight 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate,
  • preferred agents according to the invention contain (a) amino acid (s).
  • Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges.
  • preferred cosmetic compositions according to the invention are characterized in that they additionally contain from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, more preferably from 0 to 15% by weight and in particular from 0 to 15% by weight , 2 to 0.5 wt .-% amino acid (s), preferably (one) amino acid (s) from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.
  • Particularly preferred agents according to the invention contain based on their weight
  • a particularly preferred group of ingredients are the silicones.
  • Particularly preferred agents according to the invention preferably comprise the silicone (s) in Amounts of 0, 1 to 10 wt .-%, preferably from 0.25 to 7 wt .-% and in particular from 0.5 to 5 wt .-%, each based on the total agent.
  • x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.
  • silicones are called DIMETHICONE according to the INCI nomenclature.
  • the following compounds are preferably those compounds of the formula Si-I: (CH 3 ) 3 Si-O-Si (CH 3 ) 3, (CH 3 ) 3 Si-O- (CH 3 ) 2 Si 0-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 2 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 3 -0-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 4 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 5 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 6 -O-Si (CH 3 ) 3 ,
  • Preferred silicones which can be used according to the invention have viscosities of 0.2 to 2 mm 2 s -1 at 20 ° C., silicones having viscosities of 0.5 to 1 mm 2 s -1 being particularly preferred.
  • Particularly preferred agents according to the invention contain one or more amino-functional silicones.
  • Such silicones may e.g. through the formula
  • R in the above formula is a hydrocarbon or a hydrocarbon radical having 1 to about 6 carbon atoms
  • Q is a polar radical of the general formula -R HZ, wherein R is a divalent linking group attached to hydrogen and the radical Z.
  • Z is an organic, amino-functional radical containing at least one amino-functional group; "a” assumes values in the range of about 0 to about 2, “b” assumes values in the range of about 1 to about 3, “a” + “b” is less than or equal to 3, and “c” is a number in the range from about 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy.
  • Non-limiting examples of the radicals represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur containing radicals such as mercaptoethyl, mercaptopropyl,
  • R examples include methylene, ethylene, propylene, hexamethylene, decamethylene, - CH 2 CH (CH 3 ) CH 2 -, phenylene, naphthylene, -CH 2 CH 2 SCH 2 CH 2 -, -CH 2 CH 2 OCH 2 -, -OCH 2 CH 2 -, - OCH 2 CH 2 CH 2 -, -CH 2 CH (CH 3 ) C (O) 2 -, - (CH 2 ) 3 CC (O) 2 CH 2 -, -C 6 H 4 C 6 H 4 -, -C 6 H 4 CH 2 C 6 H 4 -; and - (CH 2 ) 3 C (O) SCH 2 CH 2 -.
  • Z is an organic, amino-functional radical containing at least one functional amino group.
  • a possible formula for Z is NH (CH 2 ) Z NH 2 , wherein z is 1 or more.
  • Another possible formula for Z is -NH (CH 2 ) Z (CH 2 ) ZZ NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl.
  • Z is most preferably a -NHCH 2 CH 2 NH 2 radical.
  • Z is - N (CH 2 ) Z (CH 2 ) ZZ NX 2 or -NX 2 , wherein each X of X 2 is independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.
  • Q is most preferably a polar, amine functional group of the formula -CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 .
  • "a” assumes values in the range of about 0 to about 2
  • "b” assumes values in the range of about 2 to about 3
  • "a” + “b” is less than or equal to 3
  • the molar ratio of the R a Qb SiO ( 4. a -b) / 2 units to the R c SiO (4 - C) / 2 units is in the range of from about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1: 15 to about 1: 20.
  • the various variable substituents in the above formula may be different for the various silicone components present in the silicone blend.
  • Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)
  • n and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.
  • compositions according to the invention which are an amino-functional silicone of the formula (Si-IIb) R- [Si (CH 3 ) 2 -O] n 1 [Si (R) -O] m - [Si (CH 3 ) 2 ] n 2 -R (Si-Ilb),
  • n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.
  • silicones are referred to as amodimethicones according to the INCI declaration.
  • agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g, are preferred ,
  • the amine number stands for the milliequivalents of amine per gram of the amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.
  • Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, particularly preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.
  • agents according to the invention which contain at least one silicone of the formula Si-III
  • x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and especially 3, 4, 5 or 6, stands.
  • the silicones described above have a backbone composed of -Si-O-Si units.
  • these Si-O-Si units may also be interrupted by carbon chains.
  • Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions.
  • R is identical or different radicals from the group -H, -phenyl, -benzyl, -CH 2 -CH (CH 3 ) Ph, the C-
  • the silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone. For aesthetic reasons, "clear" products are often preferred by consumers, hair treatment agents which are preferred according to the invention are therefore characterized by being transparent or translucent.
  • NTU Nephelometrie Turbidity Unit
  • an agent according to the invention may also contain UV filters (I).
  • the UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC ( ⁇ 280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.
  • the UV filters used according to the invention can be selected, for example, from substituted benzophenones, p-aminobenzoic acid esters, diphenylacrylic acid esters, cinnamic acid esters, salicylic acid esters, benzimidazoles and o-aminobenzoic acid esters.
  • UV filters which can be used according to the invention are 4-aminobenzoic acid, ⁇ , ⁇ , ⁇ -trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline methylsulfate, 3,3,5-trimethylcyclohexyl salicylate (homosalates), 2-hydroxy-4-methoxy-benzophenone (benzophenone-3; Uvinul ® M 40, Uvasorb MET ®, ® Neo Heliopan BB, Eusolex ® 4360), 2-phenylbenzimidazole-5-sulfonic acid and potassium, sodium and triethanolamine salts ( Phenylbenzimidazole Sulfonic Acid; Parsol ® HS; Neo Heliopan Hydro ®), 3,3 '- (1, 4-phenylenedimethylene) -bis (7J-dimethyl-2-oxo-bicyclo [2.2.1] hept-1-yl methane-sulfonic acid) and salts thereof, 1- (4-tert-buty
  • Methoxycinnamic acid isopentyl ester, 4-methoxycinnamic acid 2-ethylhexyl ester, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt, 3- (4'-methylbenzylidene) -D, L-camphor, 3-benzylidene-camphor, 4-Isopropylbenzyl salicylate, 2,4,6-trianilino (p-carbo-2'-ethylhexyl-1'-oxy) -1, 3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - ⁇ (2 and 4) - [2-oxoborn-3-ylidenemethyl] benzyl ⁇ -acrylamide.
  • the UV filters (I) are contained in the compositions according to the invention usually in amounts of 0.1-5 wt .-%, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.
  • compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J).
  • a 2-pyrrolidinone-5-carboxylic acid and its derivatives Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C 1 to C 4 alkyl groups.
  • the sodium salt is most preferred.
  • the amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total agent, more preferably 0, 1 to 5, and in particular 0, 1 to 3 wt.%.
  • compositions according to the invention contain penetration aids and / or swelling agents (M).
  • M penetration aids and / or swelling agents
  • M include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, bicarbonates, Diols and triols, and in particular 1, 2-diols and 1, 3-diols such as 1, 2-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-dodecanediol, 1, 3-propanediol, 1 , 6-hexanediol, 1, 5-pentanediol, 1, 4-
  • short-chain carboxylic acids may additionally support the active substance complex (A).
  • Short-chain carboxylic acids and their derivatives in the context of the invention are understood to mean carboxylic acids which are saturated or unsaturated and / or may be straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750.
  • preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.
  • the short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups.
  • Preferred within the meaning of the invention are carboxylic acids having a plurality of carboxy groups, in particular di- and tricarboxylic acids.
  • the carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester.
  • the carboxylic acids used according to the invention may of course be substituted along the carbon chain or the ring skeleton.
  • the substituents of the carboxylic acids used according to the invention include, for example, C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 -hydroxyalkyl, C 2 -C 8 -hydroxyalkenyl , Aminomethyl, C 2 -C 8 -aminoalkyl, cyano, formyl, oxo, thioxo, hydroxy, mercapto, amino, carboxy or imino groups.
  • Preferred substituents are C 1 -C 8 alkyl, hydroxymethyl, hydroxy, amino and carboxy groups. Particularly preferred are substituents in position.
  • substituents are hydroxyl, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals.
  • preferred carboxylic acid derivatives are the phosphonic and phosphate esters.
  • the agents according to the invention may contain emulsifiers (F).
  • Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion.
  • Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions.
  • An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants.
  • the selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion.
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
  • compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18.
  • Nonionic emulsifiers having an HLB value of 10 to 15 may be particularly preferred according to the invention.
  • the anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups.
  • anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
  • the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid which is commercially available, for example under the name Rheothik ® 1 1-80 is.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer.
  • anionic monomers reference is made to the substances listed above.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt is present.
  • This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • This compound which in addition to the polymer component contains a hydrocarbon mixture (Ci 3 -Ci 4 -lsopar
  • anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ® commercially. Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers. A 1, 9-decadiene crosslinked maleic acid methyl vinyl ether copolymer is available under the name ® Stabileze QM.
  • the agents according to the invention may contain nonionic polymers (G4).
  • Suitable nonionic polymers are, for example:
  • Vinylpyrrolidone / vinyl ester copolymers as sold, for example, under the trademark Luviskol ® (BASF).
  • Luviskol ® VA 64 and Luviskol ® VA 73, each vinylpyrrolidone / vinyl acetate copolymers are also preferred nonionic polymers.
  • Cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylcellulose Methylhy-, as sold for example under the trademark Culminal® ® and Benecel ® (AQUALON) and Natrosol ® grades (Hercules).
  • Starch and its derivatives in particular starch, such as Structure XL ® (National Starch), a multifunctional, salt-tolerant starch;
  • Siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups. Glycosidically substituted silicones.
  • the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.
  • the other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0, 1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.
  • Another object of the present invention is a method for the treatment of keratinic fibers, in particular human hair, in which a hair treatment agent according to the invention applied to keratinic fibers and leave there either until the next hair wash (so-called “leave-on” product) or after Exposure time of 30 to 300 seconds rinsed out (so-called rinse-off product) is.
  • n stands for integers between 5 and 100

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

Agents antipelliculaires à effet rapide, doux pour le cuir chevelu et pour les cheveux et n'ayant pas d'influence négative sur les cheveux en termes de brillance, de souplesse et de peignabilité. Ces agents contiennent, relativement à leur poids, - ≥ 6 % en poids de tensioactif(s), de préférence ≥ 10 % en poids de tensioactif(s), ≥ 80 % en poids de l'ensemble des tensioactifs se présentant sous forme de tensioactifs amphotères et/ou non ioniques et 0,0001 à 5 % en poids de epsilon-poly-L-lysine de formule générale (I) dans laquelle n représente des chiffres entiers de 5 à 100, les compositions suivantes étant exclues: (Fig A).
EP12725415.9A 2011-07-21 2012-06-01 Agent de traitement capillaire tensioactif contenant de la poly-l-lysine ii Withdrawn EP2734181A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201110079536 DE102011079536A1 (de) 2011-07-21 2011-07-21 Tensidsiches Haarbehandlungsmittel mit Poly-L-Lysin II
PCT/EP2012/060408 WO2013010708A2 (fr) 2011-07-21 2012-06-01 Agent de traitement capillaire tensioactif contenant de la poly-l-lysine ii

Publications (1)

Publication Number Publication Date
EP2734181A2 true EP2734181A2 (fr) 2014-05-28

Family

ID=46208043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12725415.9A Withdrawn EP2734181A2 (fr) 2011-07-21 2012-06-01 Agent de traitement capillaire tensioactif contenant de la poly-l-lysine ii

Country Status (3)

Country Link
EP (1) EP2734181A2 (fr)
DE (1) DE102011079536A1 (fr)
WO (1) WO2013010708A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108125804A (zh) * 2018-01-29 2018-06-08 南阳师范学院 一种抑菌清爽型洗头膏及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221616A (ja) * 1986-03-22 1987-09-29 Kanebo Ltd 頭髪化粧料
US5136093A (en) 1991-02-06 1992-08-04 Smith Ronald J Quaternized panthenol compounds and their use
JP2004026743A (ja) * 2002-06-27 2004-01-29 Chisso Corp ポリリジン製剤およびこれを含有する化粧料組成物
JP2007153791A (ja) * 2005-12-05 2007-06-21 Lion Corp シャンプー組成物
FR2922446A1 (fr) * 2007-10-19 2009-04-24 Oreal Composition comprenant au moins une polylysine et au moins un agent alcalin particulier, procede de coloration et/ou de decoloration des fibres keratiniques
WO2009150090A2 (fr) * 2008-06-12 2009-12-17 Basf Se Préparations cosmétiques pour éviter les odeurs corporelles
JP4947034B2 (ja) * 2008-10-30 2012-06-06 Ｊｎｃ株式会社 ポリリジン製剤およびこれを含有する化粧料組成物
DE102010043073A1 (de) * 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Wirkstoffkombination und Haarbehandlungsgmittel gegen Schuppen IV
DE102010043076A1 (de) * 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen II
DE102010043075A1 (de) * 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen I
DE102010043074A1 (de) * 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen III
DE102010062662A1 (de) 2010-12-08 2012-06-14 Henkel Ag & Co. Kgaa Wirkstoffkombination und Haarbehandlungsmittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013010708A2 *

Also Published As

Publication number Publication date
WO2013010708A3 (fr) 2013-09-26
WO2013010708A2 (fr) 2013-01-24
DE102011079536A1 (de) 2013-01-24

Similar Documents

Publication Publication Date Title
EP2734176B1 (fr) Association de principes actifs à effet accru et agent de traitement capillaire antipelliculaire ii
DE102010043074A1 (de) Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen III
DE102008038137A1 (de) Sulfatfreies mildes Tensidsystem zur Haut- und Haarreinigung
DE102009048299A1 (de) Haarbehandlungsmittel mit Tensid(en) und Proteolipid(en)
DE102010043075A1 (de) Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen I
EP2632417A1 (fr) Combinaison d'actifs et agents pour traiter les cheveux contre les pellicules ii
WO2009024360A1 (fr) Agents de traitement capillaire contenant un ou plusieurs tensioactifs et mélatonine/agomélatine
DE102010043073A1 (de) Wirkstoffkombination und Haarbehandlungsgmittel gegen Schuppen IV
DE102011087343A1 (de) Haarbehandlungsmittel mit 4-morpholinomethyl-substituierten Silikon(en)
EP2775998A2 (fr) Produits de soins capillaires
DE102010062662A1 (de) Wirkstoffkombination und Haarbehandlungsmittel
DE102011079540A1 (de) Leistungsgesteigerte Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen I
WO2013010708A2 (fr) Agent de traitement capillaire tensioactif contenant de la poly-l-lysine ii
DE102007058845A1 (de) Haarreinigungsmittel mit Tensid-/Verdickerkombination
EP2734182B1 (fr) Agent de traitement capillaire tensioactif contenant de la poly-l-lysine i
EP2779985B1 (fr) Produits de soins capillaires
DE102011079666A1 (de) Kosmetische Zusammensetzung enthaltend Öl aus den Samen der Kapkastanie
DE102007062520A1 (de) Haarreinigungsmittel mit Strukturantien
EP2734183A2 (fr) Agent de traitement capillaire alcoolique contenant de la poly-l-lysine
WO2013026619A1 (fr) Produit de soins capillaires contenant un principe actif cationique et présentant une aptitude à l'écoulement optimisée
DE102011083313A1 (de) Haarbehandlungsmittel mit kationischem Pflegestoff und Tensid(en)
DE102011083312A1 (de) Haarbehandlungsmittel mit kationischem Pflegestoff und Silikon(en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150210

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160728

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161208